Friday - December 12, 2025
Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial
December 10, 2025
PHILADELPHIA, Pennsylvania, Dec. 10 [Category: Medical] -- The American Association for Cancer Research posted the following news release:

* * *

Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

Benefit was seen across all subgroups, including in patients with brain metastasis

* 

SAN ANTONIO - Adding tucatinib (Tukysa) to first-line mainte . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products